Equity Overview
Price & Market Data
Price: $4.30
Daily Change: +$0.17 / 3.95%
Range: $4.13 - $4.36
Market Cap: $658,863,232
Volume: 1,689,322
Performance Metrics
1 Week: 4.90%
1 Month: -27.09%
3 Months: 25.51%
6 Months: 41.25%
1 Year: 140.5%
YTD: 26.25%
Company Details
Employees: 394
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.